ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19
Study Details
Study Description
Brief Summary
This is a platform trial to conduct a series of randomized, double-blind, placebo-controlled trials using common assessments and endpoints in hospitalized adults diagnosed with Coronavirus Disease 2019 (COVID-19). Big Effect Trial (BET) is a proof-of-concept study with the intent of identifying promising treatments to enter a more definitive study. The study will be conducted in up to 70 domestic sites and 5 international sites. The study will compare different investigational therapeutic agents to a common control arm and determine which have relatively large effects. In order to maintain the double blind, each intervention will have a matched placebo. However, the control arm will be shared between interventions and may include participants receiving the matched placebo for a different intervention.
The goal is not to determine clear statistical significance for an intervention, but rather to determine which products have clinical data suggestive of efficacy and should be moved quickly into larger studies. Estimates produced from BET will provide an improved basis for designing the larger trial, in terms of sample size and endpoint selection. Products with little indication of efficacy will be dropped on the basis of interim evaluations. In addition, some interventions may be discontinued on the basis of interim futility or efficacy analyses.
One or more interventions may be started at any time. The number of interventions enrolling are programmatic decisions and will be based on the number of sites and the pace of enrollment. At the time of enrollment, subjects will be randomized to receive any one of the active arms they are eligible for or placebo. Approximately 200 (100 treatment and 100 shared placebo) subjects will be assigned to each arm entering the platform and a given site will generally have no more than 3 interventions at once.
The BET-A stage will evaluate the combination of remdesivir with risankizumab vs remdesivir with a risankizumab placebo. The primary objective is to evaluate the clinical efficacy of different investigational therapeutics relative to the control arm in adults hospitalized with COVID-19 according to clinical status (8-point ordinal scale) at Day 8.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
This is a platform trial to conduct a series of randomized, double-blind, placebo-controlled trials using common assessments and endpoints in hospitalized adults diagnosed with Coronavirus Disease 2019 (COVID-19). Big Effect Trial (BET) is a proof-of-concept study with the intent of identifying promising treatments to enter a more definitive study. The study will be conducted in up to 70 domestic sites and 5 international sites. The study will compare different investigational therapeutic agents to a common control arm and determine which have relatively large effects. In order to maintain the double blind, each intervention will have a matched placebo. However, the control arm will be shared between interventions and may include participants receiving the matched placebo for a different intervention.
The goal is not to determine clear statistical significance for an intervention, but rather to determine which products have clinical data suggestive of efficacy and should be moved quickly into larger studies. Estimates produced from BET will provide an improved basis for designing the larger trial, in terms of sample size and endpoint selection. Products with little indication of efficacy will be dropped on the basis of interim evaluations. In addition, some interventions may be discontinued on the basis of interim futility or efficacy analyses.
One or more interventions may be started at any time. The number of interventions enrolling are programmatic decisions and will be based on the number of sites and the pace of enrollment. At the time of enrollment, subjects will be randomized to receive any one of the active arms they are eligible for or placebo. Approximately 200 (100 treatment and 100 shared placebo) subjects will be assigned to each arm entering the platform and a given site will generally have no more than 3 interventions at once.
The BET-A stage will evaluate the combination of remdesivir with risankizumab vs remdesivir with a risankizumab placebo. Subjects will be assessed daily while hospitalized. Once subjects are discharged from the hospital, they will have a study visit at Days 8, 15, 22, 29, and 60 as an outpatient. The Day 8, Day 22 and Day 60 visits do not have laboratory tests or collection of samples and may be conducted by phone. All subjects will undergo a series of efficacy and safety laboratory assessments. Safety laboratory tests and blood (serum and plasma) research samples and oropharyngeal (OP) swabs will be obtained on Day 1 (prior to study product administration) and Days 3, 5, 8, and 11 while hospitalized. OP swabs (oropharyngeal swabs are preferred, but if these are not obtainable, saliva or nasopharyngeal or nasal swabs may be substituted) and blood research samples plus safety laboratory tests will be collected on Day 15 and 29 if the subject attends an in-person visit or is still hospitalized. However, if infection control considerations or other restrictions prevent the subject from returning to the clinic, Day 15 and 29 visits may be conducted by phone and only clinical data will be obtained.
The primary objective is to evaluate the clinical efficacy of different investigational therapeutics relative to the control arm in adults hospitalized with COVID-19 according to clinical status (8-point ordinal scale) at Day 8. The key secondary objectives are 1) to evaluate the clinical efficacy of different investigational therapeutics as assessed by time to recovery compared to the control arm, and 2) to evaluate the proportion of subjects alive and without respiratory failure through Day 29.
Contacts:
20-0013 Central Contact
Telephone: 1 (301) 7617948
Email: DMIDClinicalTrials@niaid.nih.gov
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Remdesivir + Placebo 200-mg intravenous (IV) remdesivir loading dose on Day 1, followed by a 100-mg once-daily IV maintenance dose up to a 10-day total course while hospitalized and 1200-mg IV risankizumab placebo infusion (300-mg x 4 vials) once on Day 1. N=100. |
Other: Placebo
Risankizumab placebo will be given at an equal volume at the same schedule.
Drug: Remdesivir
Remdesivir is a single diastereomer monophosphoramidate prodrug for the intracellular delivery of a modified adenine nucleoside analog GS-441524.
|
| Experimental: Remdesivir + Risankizumab 200-mg intravenous (IV) remdesivir loading dose on Day 1, followed by a 100-mg once-daily IV maintenance dose up to a 10-day total course while hospitalized and 1200-mg IV risankizumab infusion (300-mg x 4 vials) once on Day 1. N=100. |
Drug: Remdesivir
Remdesivir is a single diastereomer monophosphoramidate prodrug for the intracellular delivery of a modified adenine nucleoside analog GS-441524.
Biological: Risankizumab
Risankizumab is a humanized immunoglobulin (Ig) G1 antagonistic monoclonal antibody (mAb) directed against the p19 subunit of the human cytokine interleukin-23. Risankizumab is formulated in a buffer of 4.4 mM disodium succinate hexahydrate/succinic acid, 225 mM sorbitol, 0.2 mg/mL polysorbate 20, and WFI in a 6R vial.
|
Outcome Measures
Primary Outcome Measures
- Clinical status on an 8-point ordinal scale. [Day 8]
Clinical status assessed using ordinal scale: 1) Not hospitalized, no new or increased limitations on activities; 2) Not hospitalized, but new or increased limitation on activities and/or requiring new or increased home oxygen, continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP); 3) Hospitalized, not requiring new or increased supplemental oxygen and no longer requires ongoing medical care; 4) Hospitalized, not requiring new or increased supplemental oxygen but requiring ongoing medical care (COVID-19 related or otherwise); 5) Hospitalized, requiring new or increased supplemental oxygen; 6) Hospitalized, requiring new or increased non-invasive ventilation or high flow oxygen devices; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 8) Death.
Secondary Outcome Measures
- Change from baseline of inflammation and coagulation markers [Day 1 through Day 29]
Markers include C-reactive protein (CRP), ferritin, D-dimer and fibrinogen.
- Change in alanine aminotransferase (ALT) over time [Day 1 through Day 29]
- Change in aspartate transaminase (AST) over time [Day 1 through Day 29]
- Change in creatinine over time [Day 1 through Day 29]
- Change in hemoglobin over time [Day 1 through Day 29]
- Change in international normalized ratio (INR) over time [Day 1 through Day 29]
- Change in platelets over time [Day 1 through Day 29]
- Change in total bilirubin over time [Day 1 through Day 29]
- Change in white blood cell (WBC) count with differential over time [Day 1 through Day 29]
- Clinical status on an 8-point ordinal scale. [Day 15 through Day 29]
Clinical status assessed using ordinal scale: 1) Not hospitalized, no new or increased limitations on activities; 2) Not hospitalized, but new or increased limitation on activities and/or requiring new or increased home oxygen, continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP); 3) Hospitalized, not requiring new or increased supplemental oxygen and no longer requires ongoing medical care; 4) Hospitalized, not requiring new or increased supplemental oxygen but requiring ongoing medical care (COVID-19 related or otherwise); 5) Hospitalized, requiring new or increased supplemental oxygen; 6) Hospitalized, requiring new or increased non-invasive ventilation or high flow oxygen devices; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 8) Death.
- Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs) [Day 1 through Day 60]
- Cumulative incidence of serious adverse events (SAEs) [Day 1 through Day 60]
- Discontinuation or temporary suspension of study product administration [Day 1 through Day 29]
For any reason.
- Duration of hospitalization [Day 1 through Day 29]
Measured in days.
- Duration of new mechanical ventilation or extracorporeal membrane oxygenation (ECMO) use [Day 1 through Day 29]
Measured in days.
- Duration of new non-invasive ventilation or high flow oxygen use during the study [Day 1 through Day 29]
Measured in days.
- Duration of non-invasive ventilation/high flow oxygen use [Day 1 through Day 29]
Measured in days.
- Incidence of new mechanical ventilation or extracorporeal membrane oxygenation (ECMO) use [Day 1 through Day 29]
- Incidence of new non-invasive ventilation or high flow oxygen use [Day 1 through Day 29]
- Mean change in the ordinal scale [Day 1 through Day 29]
Clinical status assessed using ordinal scale: 1) Not hospitalized, no new or increased limitations on activities; 2) Not hospitalized, but new or increased limitation on activities and/or requiring new or increased home oxygen, continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP); 3) Hospitalized, not requiring new or increased supplemental oxygen and no longer requires ongoing medical care; 4) Hospitalized, not requiring new or increased supplemental oxygen but requiring ongoing medical care (COVID-19 related or otherwise); 5) Hospitalized, requiring new or increased supplemental oxygen; 6) Hospitalized, requiring new or increased non-invasive ventilation or high flow oxygen devices; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 8) Death.
- Proportion of subjects alive and without respiratory failure [Day 29]
Subjects in ordinal scale 5 or 6 at baseline who did not meet either of the following two categories on Day 29: 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 8) Death.
- Subject mortality [Day 1 through Day 60]
Date and cause of death (if applicable).
- Supplemental oxygen use [Day 1 through Day 29]
Measured in days.
- Time to an improvement of one category using an ordinal scale [Day 1 through Day 29]
Clinical status assessed using ordinal scale: 1) Not hospitalized, no new or increased limitations on activities; 2) Not hospitalized, but new or increased limitation on activities and/or requiring new or increased home oxygen, continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP); 3) Hospitalized, not requiring new or increased supplemental oxygen and no longer requires ongoing medical care; 4) Hospitalized, not requiring new or increased supplemental oxygen but requiring ongoing medical care (COVID-19 related or otherwise); 5) Hospitalized, requiring new or increased supplemental oxygen; 6) Hospitalized, requiring new or increased non-invasive ventilation or high flow oxygen devices; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 8) Death.
- Time to an improvement of two categories using an ordinal scale [Day 1 through Day 29]
Clinical status assessed using ordinal scale: 1) Not hospitalized, no new or increased limitations on activities; 2) Not hospitalized, but new or increased limitation on activities and/or requiring new or increased home oxygen, continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP); 3) Hospitalized, not requiring new or increased supplemental oxygen and no longer requires ongoing medical care; 4) Hospitalized, not requiring new or increased supplemental oxygen but requiring ongoing medical care (COVID-19 related or otherwise); 5) Hospitalized, requiring new or increased supplemental oxygen; 6) Hospitalized, requiring new or increased non-invasive ventilation or high flow oxygen devices; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 8) Death.
- Time to death [Day 1 through Day 29]
- Time to recovery [Day 1 through Day 29]
Day of recovery is defined as the first day on which the subject satisfies 1 of the following 3 categories from the ordinal scale (and does not return to a score of 4 or higher for the remainder of the study period): 1) Not hospitalized, no new or increased limitations on activities; 2) Not hospitalized, but new or increased limitation on activities and/or requiring new or increased home oxygen, continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP); 3) Hospitalized, not requiring new or increased supplemental oxygen - no longer requires ongoing medical care.
- Ventilator/ extracorporeal membrane oxygenation (ECMO) use [Day 1 through Day 29]
Measured in days.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Admitted to a hospital with symptoms suggestive of Coronavirus Disease 2019 (COVID-19) and requires ongoing medical care.
-
Subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures.
-
Subject (or legally authorized representative) understands and agrees to comply with planned study procedures.
-
Male or non-pregnant female adult >/= 18 years of age at time of enrollment.
-
Illness of any duration and has laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection as determined by polymerase chain reaction (PCR) or other commercial or public health assay (e.g., Nucleic Acid Amplification Test [NAAT], antigen test) in any respiratory specimen or saliva </=14 days prior to randomization.
-
Illness of any duration, and requiring, just prior to randomization, supplemental oxygen (any flow), mechanical ventilation or ECMO (ordinal score 5, 6, or 7).
-
Women of childbearing potential must agree to either abstinence or use at least one acceptable method of contraception from the time of screening through 5 months post study IP dosing.
Note: Acceptable methods include barrier contraceptives (condoms or diaphragm) with spermicide, intrauterine devices (IUDs), hormonal contraceptives, oral contraceptive pills, and surgical sterilization.
- Agrees not to participate in another blinded clinical trial (both pharmacologic and other types of interventions) for the treatment of COVID-19 through Day 29.
Exclusion Criteria:
-
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 times the upper limit of normal.
-
Subjects with a low glomerular filtration rate (eGFR), specifically:
-
Subjects with an a glomerular filtration rate (eGFR) 20-30 mL/min are excluded unless in the opinion of the principal investigator (PI), the potential benefit of participation outweighs the potential risk of study participation.
-
All subjects with an a glomerular filtration rate (eGFR) <20 mL/min (including hemodialysis and hemofiltration) are excluded.
-
Pregnancy or breast feeding.
-
Anticipated discharge from the hospital or transfer to another hospital which is not a study site within 72 hours of enrollment.
-
Allergy to any study medication.
-
Received five or more doses of remdesivir prior to screening.
-
Received two or more doses of > 60 mg of prednisone or equivalent in the 7 days prior to screening.
-
Received small molecule tyrosine kinase inhibitors, including Janus kinase (JAK) inhibitors (e.g., baricitinib, ibrutinib, acalabrutinib, imatinib, gefitinib), in the 4 weeks prior to screening.
-
Received monoclonal antibodies targeting cytokines (e.g., tumor necrosis factor (TNF) inhibitors, anti-IL-1 [e.g., anakinra, canakinumab], anti-IL-6 [e.g., tocilizumab, sarilumab, sitlukimab]), or T-cells (e.g., abatacept) in the 4 weeks prior to screening.
-
Received monoclonal antibodies targeting B-cells (e.g., rituximab, and including any targeting multiple cell lines including B-cells) in the 3 months prior to screening.
-
Received Granulocyte-macrophage colony-stimulating factor (GM-CSF) agents (e.g., sargramostim) within 2 months prior to screening.
-
Received other immunosuppressants in the 4 weeks prior to screening and in the judgment of the investigator, the risk of immunosuppression with risankizumab is larger than the risk of Coronavirus Disease 2019 (COVID-19).
-
Received any live vaccine in the 4 weeks prior to screening.
-
Known active tuberculosis.
-
Known history of Human Immunodeficiency Virus (HIV), Hepatitis B (HBV) or untreated hepatitis C (HCV) infection.
-
History of pulmonary alveolar proteinosis (PAP).
-
Has a malignancy and currently receiving immunosuppressive chemotherapy, immunodeficiency, uncontrolled opportunistic infection, or uncontrolled cirrhosis.
-
Has a medical condition that could, in the judgment of the investigator, limit the interpretation and generalizability of trial results.
-
Positive test for influenza virus during the current illness (influenza testing is not required by protocol).
-
Previous participation in an ACTIV-5/Big Effect Trial (BET)
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | The University of Arizona - Banner University Medical Center Tucson Campus - Tucson | Tucson | Arizona | United States | 85724-0001 |
| 2 | University of Arkansas for Medical Sciences | Little Rock | Arkansas | United States | 72205-7101 |
| 3 | Kern Medical Center | Bakersfield | California | United States | 93306-4018 |
| 4 | UCSF Fresno Center for Medical Education and Research - Clinical Research Center | Fresno | California | United States | 93721 |
| 5 | Hoag Hospital Newport Beach | Newport Beach | California | United States | 92663 |
| 6 | Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases | Stanford | California | United States | 94305-2200 |
| 7 | Penrose Hospital - Emergency Medicine | Colorado Springs | Colorado | United States | 80907 |
| 8 | St. Francis Medical Center | Colorado Springs | Colorado | United States | 80923 |
| 9 | St. Anthony Hospital | Lakewood | Colorado | United States | 80228-1704 |
| 10 | St. Anthony Hospital North Health Campus | Westminster | Colorado | United States | 80023 |
| 11 | Nuvance Health Danbury Hospital - Infectious Disease | Danbury | Connecticut | United States | 06810 |
| 12 | Yale School of Medicine - The Anlyan Center for Medical Research & Education - Immunobiology | New Haven | Connecticut | United States | 06519-1612 |
| 13 | Nuvance Health - Norwalk Hospital - Asthma Pulmonary and Critical Care Medicine | Norwalk | Connecticut | United States | 06856 |
| 14 | University of Florida Health - Shands Hospital - Division of Infectious Diseases and Global Medicine | Gainesville | Florida | United States | 32610 |
| 15 | Grady Memorial Hospital | Atlanta | Georgia | United States | 30303 |
| 16 | Emory Vaccine Center - The Hope Clinic | Decatur | Georgia | United States | 30030-1705 |
| 17 | Cook County Health and Hospitals System - Ruth M Rothstein CORE Center | Chicago | Illinois | United States | 60612 |
| 18 | Rush University Medical Center | Chicago | Illinois | United States | 60612 |
| 19 | Great Lakes Clinical Trials | Chicago | Illinois | United States | 60640 |
| 20 | Carle Foundation Hospital | Urbana | Illinois | United States | 61801 |
| 21 | Northwestern Medicine - Central DuPage Hospital - Infectious Disease | Winfield | Illinois | United States | 60190 |
| 22 | Norton Healthcare | Louisville | Kentucky | United States | 40202 |
| 23 | University of Louisville - Division of Infectious Diseases | Louisville | Kentucky | United States | 40202 |
| 24 | Pikeville Medical Center - Department of Infectious Disease | Pikeville | Kentucky | United States | 41501 |
| 25 | Brigham and Women's Hospital - Infectious Diseases | Boston | Massachusetts | United States | 02115-6110 |
| 26 | Boston Medical Center - Center for Infectious Diseases - Shapiro Center | Boston | Massachusetts | United States | 02118-2526 |
| 27 | Hennepin Healthcare Research Institute | Minneapolis | Minnesota | United States | 55415 |
| 28 | Englewood Hospital | Englewood | New Jersey | United States | 07631 |
| 29 | Jacobi Medical Center | Bronx | New York | United States | 10461-1119 |
| 30 | The State University of New York - University at Buffalo - Department of Medicine | Buffalo | New York | United States | 14203 |
| 31 | Mount Sinai School of Medicine - Medicine - Infectious Diseases | New York | New York | United States | 10029-6504 |
| 32 | Nuvance Health - Vassar Brothers Medical Center | Poughkeepsie | New York | United States | 12601 |
| 33 | Stony Brook Medicine - Stony Brook University Hospita | Stony Brook | New York | United States | 11794 |
| 34 | East Carolina University Brody School of Medicine - Adult Specialty Care | Greenville | North Carolina | United States | 27834 |
| 35 | Wake Forest Baptist Health - Infectious Diseases | Winston-Salem | North Carolina | United States | 27157 |
| 36 | University of Toledo Medical Center - Ruppert Clinic | Toledo | Ohio | United States | 43614 |
| 37 | St. Charles Health System - St. Charles Bend Hospital | Bend | Oregon | United States | 97701 |
| 38 | Doylestown Hospital | Doylestown | Pennsylvania | United States | 18901 |
| 39 | Kent County Memorial Hospital | Warwick | Rhode Island | United States | 02886 |
| 40 | Monument Health - Clinical Research | Rapid City | South Dakota | United States | 57701 |
| 41 | Hendrick Health - Hendrick Medical Center | Abilene | Texas | United States | 79601 |
| 42 | Texas Tech University Health Science Center | Amarillo | Texas | United States | 79106 |
| 43 | Baptist Hospitals of Southeast Texas Site | Beaumont | Texas | United States | 77701 |
| 44 | Methodist Hospital - Houston | Houston | Texas | United States | 77030 |
| 45 | University of Texas Health Science Center at Tyler | Tyler | Texas | United States | 75708-3154 |
| 46 | West Virginia University - Infectious Diseases Clinic | Morgantown | West Virginia | United States | 26506 |
Sponsors and Collaborators
- National Institute of Allergy and Infectious Diseases (NIAID)
Investigators
None specified.Study Documents (Full-Text)
More Information
Publications
None provided.- 20-0013A